Search Results - "Byers, L.A."

Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix by Frumovitz, M, Munsell, M.F, Burzawa, J.K, Byers, L.A, Ramalingam, P, Brown, J, Coleman, R.L

“…Abstract Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of…”
Get full text

242 BMN 673 as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer models by Feng, Y, Post, L.E, Cardnell, R, Byers, L.A, Wang, B, Shen, Y

Get full text

243 Modulation of PI3K/mTOR pathway following PARP inhibition in small cell lung cancer by Cardnell, R.J, Feng, Y, Diao, L, Fan, Y, Masrorpour, F, Mukherjee, S, Shen, J, Wang, J, Byers, L.A

Get full text

435 A pan-cancer tumor-derived epithelial-to–mesenchymal transition (EMT) signature determines patterns of drug sensitivity and enrichment in immune target expression following EMT by Mak, M.P, Tong, P, Diao, L, Ng, P.K.S, Fan, Y, Cardnell, R.J, Gibbons, D.L, William, W.N, Heymach, J.V, Coombes, K.R, Byers, L.A, Wang, J

Get full text

388 An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors by Cardnell, R.J, Behrens, C, Diao, L, Fan, Y, Tang, X, Minna, J.D, Mills, G.B, Heymach, J.V, Wistuba, I.I, Wang, J, Byers, L.A

Get full text

Implications of KRAS Mutations on Outcomes in Non-small Cell Lung Cancer Treated With Radiation Therapy by Welsh, J.W, Likacheva, A, Byers, L.A, Bhardwaj, V, Diao, L, Wang, J, Ang, K, Komaki, R, Kim, E, Heymach, J.V

Get full text

1668TiP Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC) by Dowlati, A., Byers, L.A., Johnson, M.L., Aljumaily, R., Prenen, H., Zhang, A., Minocha, M., Shetty, A., Hashemi Sadraei, N.

Get full text

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer by Subbiah, V., Shen, T., Tetzlaff, M., Weissferdt, A., Byers, L.A., Cascone, T., Behrang, A., Meric-Bernstam, F., Mooers, B.H.M., Rothenberg, S.M., Ebata, K., Wu, J.

Get full text

Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer by Federico, L., McGrail, D.J., Bentebibel, S.-E., Haymaker, C., Ravelli, A., Forget, M.-A., Karpinets, T., Jiang, P., Reuben, A., Negrao, M.V., Li, J., Khairullah, R., Zhang, J., Weissferdt, A., Vaporciyan, A.A., Antonoff, M.B., Walsh, G., Lin, S.-Y., Futreal, A., Wistuba, I., Roth, J., Byers, L.A., Gaudreau, P.-O., Uraoka, N., Cruz, A.F., Dejima, H., Lazcano, R.N., Solis, L.M., Parra, E.R., Lee, J.J., Swisher, S., Cascone, T., Heymach, J.V., Zhang, J., Sepesi, B., Gibbons, D.L., Bernatchez, C.

“…Despite the importance of tumor-infiltrating T lymphocytes (TILs) in cancer biology, the relationship between TIL phenotypes and their prognostic relevance for…”
Get full text

The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers by Kundu, S T, Byers, L A, Peng, D H, Roybal, J D, Diao, L, Wang, J, Tong, P, Creighton, C J, Gibbons, D L

“…Metastatic lung cancer is one of the most lethal forms of cancer and molecular pathways driving metastasis are still not clearly elucidated. Metastatic cancer…”
Get full text

Genomic landscape of small cell neuroendocrine cervical cancer by Hillman, R.T., Cardnell, R., Fujimoto, J., Byers, L.A., Futreal, P.A., Frumovitz, M.

Get full text

SCLC subtype-enriched biomarkers define positioning of Aurora B inhibitor combination with venetoclax by Della Corte, C., Gay, C., Urosevic, J., Polanska, U., Ajpacaja, L., Wijnhoven, P., Wang, J., Coker, E., Fabbri, G., Jaaks, P., Jerome, M., Cosaert, J., Garnett, M., Cardnell, R., Pease, J.E., Travers, J., Byers, L.A.

Get full text

1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer by Ramkumar, K., Stewart, C.A., Gay, C., Cardnell, R., Diao, L., Wang, Q., Shen, L., Xi, Y., Kundu, S., Della Corte, C., Gibbons, D., Wang, J., Heymach, J.V., Byers, L.A.

Get full text

1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models by Stewart, C.A., Gay, C., Ramkumar, K., Cargill, K.R., Cardnell, R., Nilsson, M., Heeke, S., Park, E.M., Kundu, S., Diao, L., Wang, Q., Shen, L., Xi, Y., Della Corte, C.M., Kundu, K., Gibbons, D.L., Wang, J., Heymach, J.V., Byers, L.A.

Get full text

1745P SARS-CoV-2 infects metabolically-primed epithelial cells in lung cancer models by Cargill, K.R., Stewart, C.A., Gay, C., Ramkumar, K., Cardnell, R., Nilsson, M., Heeke, S., Park, E.M., Diao, L., Wang, Q., Shen, L., Le, X., Xi, Y., Kundu, K., Gibbons, D., Wang, J., Heymach, J.V., Byers, L.A.

Get full text

VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo) by Liu, S.V., Mok, T.S.K., Mansfield, A.S., De Boer, R.H., Losonczy, G., Sugawara, S., Krzakowski, M.J., Smolin, A., Hochmair, M.J., Garassino, M.C., Gay, C.M., Heymach, J.V., Byers, L.A., McCleland, M., Nabet, B.Y., Morris, S., Adler, L., Shames, D., Reck, M.

Get full text

1749P - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer by Della Corte, C.M., Ajpacaja, L., Cardnell, R.J., Gay, C.M., Wang, Q., Shen, L., Ramkumar, K., Stewart, A.C., Fan, Y.-H., Adelman, C.A., Travers, J., Wang, J., Heymach, J., Byers, L.A.

“…Aurora Kinases (AURK) regulate mitosis and are often upregulated in cancer. SCLC is characterized by TP53 and RB1 loss and frequent MYC amplification. Our…”
Get full text

Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer by Della Corte, C.M., Ajpacaja, L., Cardnell, R.J., Gay, C.M., Wang, Q., Shen, L., Ramkumar, K., Stewart, A.C., Fan, Y.-H., Adelman, C.A., Travers, J., Wang, J., Heymach, J., Byers, L.A.

Get full text

16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer by Le, X., Elamin, Y.Y., Altan, M., Blumenschein, G., Byers, L.A., Cascone, T., Skoulidis, F., Gay, C., Tsao, A.S., Gibbons, D., Negrao, M.V., Vokes, N., Zhang, J., Heeke, S., Rotow, J., Jänne, P.A., Pellini, B., Tu, J., Gray, J.E., Heymach, J.

Get full text

33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models by Meric-Bernstam, F., Yuca, E., Evans, K., Zhao, M., Raso, M.G., Maejima, T., Zheng, X., Rizvi, Y., Akcakanat, A., Scott, S., Wang, B., Byers, L.A., Tripathy, D., Okajima, D., Damodaran, S.

Get full text